Inactivation of Acetyl-CoA Acyltransferase 1 enhances the proliferation and motility of nasopharyngeal carcinoma cells

乙酰辅酶A酰基转移酶1的失活增强了鼻咽癌细胞的增殖和迁移能力。

阅读:1

Abstract

Acetyl-CoA acyltransferase 1 (ACAA1), encoding the peroxisomal 3-ketoacyl-CoA thiolase (POT1), plays a pivotal role in the fatty acid beta-oxidation pathway. Accumulating evidence has linked this enzyme to the onset and development of diverse human malignancies. Here, we observed a marked downregulation of ACAA1 in nasopharyngeal carcinoma (NPC), which displayed an inverse correlation with the expression genes coded by Epstein-Barr virus (EBV). Receiver operating characteristic (ROC) curve and Kaplan-Meier survival analysis highlighted the potential of ACAA1 as a valuable diagnostic and prognostic biomarker for NPC. Next, gain-of- function experiments were conducted, and the results vividly illustrated that overexpression of ACAA1 potently impeded the proliferation, migration, and invasion of NPC cells. The inhibitory effect was further verified by the reduced Ki-67 staining intensity and the altered distribution pattern of actin filaments, which are crucial indicators of cell proliferation and motility. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses revealed significant enrichment of immune-related pathways in NPC cells with elevated ACAA1 expression. Moreover, comprehensive xCell, ESTIMATE, and Immunophenoscore analyses underscored the positive association between ACAA1 and immune cell infiltration and the tumor immune effective microenvironment in NPC. Especially, a positive correlation between ACAA1 expression in tumor cells and six immune checkpoint-related genes, namely CD27, PDCD1, CD86, BTLA, TIGIT, and CD28, on immune cells within the tumor microenvironment. Collectively, our findings highlight the potential of ACAA1 as a tumor - suppressor gene and suggest its possible involvement in the immune evasion mechanisms of NPC. This study may provide novel insights into the molecular pathogenesis of NPC and offer new therapeutic targets for this malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。